Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Immune Response to a Murine Coronavirus: Identification of a Homing Receptor-Negative CD4+ T Cell Subset That Responds to Viral Glycoproteins

JAMES MOBLEY,* GREGORY EVANS,† MORRIS O. DAILEY,** and STANLEY PERLMAN*†

Departments of *Microbiology, †Pediatrics, and ‡Pathology, University of Iowa, Iowa City, Iowa 52242

Received November 1, 1991; accepted December 5, 1991

The lymphocyte proliferative response to mouse hepatitis virus, strain JHM (MHV-JHM), a well-described cause of chronic and acute neurological infections, has been studied using vaccinia virus recombinants expressing individual MHV proteins. The surface (S) and transmembrane (M) glycoproteins were the most active proteins in causing proliferation of lymphocytes isolated from immunized adult mice, whereas lymphocytes from persistently infected mice proliferated only in response to the S protein. The cells from immunized mice which proliferated most actively in response to MHV were positive for the CD4 antigen and secreted interferon-γ. In addition, the most responsive subset of cells did not express gp90MEL-14, the lymph node-specific homing receptor. The results identify a subpopulation of CD4+ T cells that may be an important component of the cell-mediated immune response to this virus. The data also suggest that response to the M protein is important in preventing disease progression in C57BL/6 mice since cells which recognize this protein are absent from persistently infected mice.

INTRODUCTION

Several strains of mouse hepatitis virus (MHV), a member of the coronavirus family, cause acute and chronic demyelinating diseases in mice and rats (Cheever et al., 1949; Weiner, 1973; Lampert et al., 1983; Nagashima et al., 1983; Sorensen et al., 1980; Stohlman and Weiner, 1981; Siddell et al., 1983). Demyelination most likely results from lytic destruction of oligodendrocytes, although immunopathological mechanisms may contribute to the process (Weiner, 1973; Lampert et al., 1973; Watanabe et al., 1983; Wang et al., 1990).

Both humoral and cellular immunity protect mice from the acute, fatal encephalitis caused by the neurotropic JHM strain of MHV (MHV-JHM). The acute MHV-JHM infection can be prevented by infusion of monoclonal antibodies directed against the surface glycoprotein (S), the transmembrane glycoprotein (M), or the nucleocapsid protein (N) (Buchmeier et al., 1984; Nakane et al., 1986; Lecomte et al., 1987; Fleming et al., 1989). Suckling mice are protected from the acute disease if they are nursed by dams previously immunized against MHV-JHM (Pickel et al., 1985; Perlman et al., 1987a). Neutralizing antibodies, however, do not appear to protect mice or rats from persistent infections caused by MHV-JHM (Weiner et al., 1973; Watanabe et al., 1987; Jacobsen and Perlman, 1990).

Cell-mediated immunity is generally believed to be crucial for control of most viral infections, and published data suggest that cellular immunity is required for control of the infection caused by MHV-JHM. Adoptive transfer of cloned CD4+ or CD8+ cells prevents the acute encephalitis, and in some cases, eradicates MHV-JHM from the central nervous system (Stohlman et al., 1986; Yamaguchi et al., 1991; Kornr et al., 1991). In other studies, adoptive transfer of nylon wool-adherent CD4+ T cells was shown to effect viral clearance in infected mice; elimination of CD8+ cells from the recipient abrogated this effect, suggesting that both CD4+ and CD8+ cells were required for maximal effect (Suezen et al., 1989). In addition, cytotoxic B cells and NK-like cells may have a role in the host immune response to MHV (Stohlman et al., 1983; Welsh et al., 1986; Carman et al., 1986).

The cell-mediated response is also important in suppressing MHV infection in rats, since nude rats or rats whose T cell response was suppressed with cyclosporin developed acute encephalomyelitis at an age when control animals were resistant to the virus (Zimmer and Dales, 1989).

In a previous report, we showed that suckling C57BL/6 mice inoculated with MHV-JHM and nursed by immunized dams were protected from the acute encephalitis, but became persistently infected with MHV-JHM. At 3–8 weeks p.i., 40–90% developed a demyelinating encephalomyelitis characterized clinically by hindlimb paralysis (Perlman et al., 1987a). With the goal of understanding the immune response in these persistently infected mice, we have compared the proliferative T cell response in these mice and that in immunized adult C57BL/6 mice. For these experi-
ments, we have used recombinant vaccinia viruses (VV) which expressed the three structural proteins (surface glycoprotein (S), the transmembrane glycoprotein (M) and the nucleocapsid protein (N)) and one nonstructural protein, p28, a basic protein encoded by the putative polymerase gene (Denison and Perlman, 1986; Soe et al., 1987). The results indicate that the cells from immunized adult mice which specifically proliferate in response to antigen are CD4+ and do not express the lymphocyte surface homing receptor, recognized by the monoclonal antibody MEL-14 (gp90MEL-14, gp90). Gp90 is a lymphocyte–endothelial adhesion molecule that mediates lymphocyte recirculation (Gallatin et al., 1983). This gp90− phenotype defines a population of high-affinity, antigen-primed effector lymphocytes in other systems (Jung et al., 1988; Bradley et al., 1991).

MATERIALS AND METHODS

Animals

Male and female MHV-negative C57BL/6 mice, 8 to 12 weeks old, were purchased from Jackson Laboratories (Bar Harbor, MA) or from Sasco Laboratories (Omaha, NE). To obtain persistently infected mice with hindlimb paralysis, suckling C57BU6 mice were inoculated intranasally with live MHV-JHM and nursed by dams with high titers of anti-MHV-JHM antibody as previously described (Perlman et al., 1987a).

Virus and cells

MHV-JHM, originally obtained from Dr. S. Weiss, University of Pennsylvania, was grown and titered as previously described (Perlman et al., 1987a). Vaccinia virus, strain WR, was obtained from the ATCC. DBT cells, derived from a murine astrocytoma (Iliarino et al., 1974), were grown in Dulbecco’s MEM supplemented with 10% fetal calf serum and antibiotics.

Construction of S, M, N, and p28 clones and of VV recombinants

A clone containing the entire MHV-JHM S gene was constructed from clones provided by Dr. S. Siddell, der Universität Würzburg, and inserted into VV as previously described (Oleszak et al., 1992). The S protein encoded in this clone was 141 amino acids shorter than its homologue from wild-type MHV-JHM (Schmidt et al., 1987; Parker et al., 1989). Wild-type MHV-JHM was used in all of the animal studies.

Clones containing the N and M proteins were obtained from Dr. S. Siddell and flanking G-C tracts removed using polymerase chain reaction (PCR) technology (Skinner and Siddell, 1983; Pfleiderer et al., 1986; Sambrook et al., 1989). To modify the N clone, a 5′ primer (AGGATGTCTTTTGTCCCTGG) and a 3′ primer (GAGTGCCGACATAGGATT) complementary to a sequence located 8 nucleotides downstream from the termination codon were used. The 5′ primer included the N initiation codon (underlined). The M clone was similarly modified using a 5′ primer containing the initiation codon (TATGAGTAGACTACTC) and a 3′ primer complementary to the sequence at the termination codon (GATTCTCAACAATACGGTG).

A clone containing p28, the 5′ terminal portion of the putative polymerase gene, was constructed using published sequences and PCR technology (Soe et al., 1987). To construct the p28 clone, a 5′ primer (GCATAATGGCAAGATGG) and a 3′ primer (TAAGGTCGCCCTTAGTCTTC) were synthesized. Since p28 is normally cleaved from a large precursor, a T nucleotide was substituted for an A present in the original sequence (underlined above) in the 3′ primer. This change introduced a termination codon into the construct at a position (amino acid 272) corresponding to a potential proteolytic cleavage site (Soe et al., 1987). The 5′ primer includes the p28 initiation codon (underlined). Complementary DNA was synthesized from MHV-JHM-infected cell RNA, using the downstream primer and M-MLV reverse transcriptase (Bethesda Research Laboratories). Using standard PCR technology, the complete double-stranded DNA molecule was constructed.

All of the above clones were inserted into the polylinker region of a VV transfer plasmid, pTM3. This plasmid includes the T7 promoter, the untranslated region of encephalomyocarditis virus, and the gene for xanthine–guanine phosphoribosyl-transferase under the control of the VV P7.5 promoter (Elroy-Stein and Moss, 1990). These sequences are flanked by VV thymidine kinase sequences to facilitate homologous recombination with VV. The Ncol site was removed with T4 DNA polymerase so that the initiation codon of each construct was used to initiate translation. HeLa cells, infected with VV strain WR, were transfected with the appropriate constructs and recombinant virus was selected and propagated as described previously (Falkner and Moss, 1988).

Immunoprecipitation

DBT cells were either infected with MHV-JHM (m.o.i. = 1) or dually infected with VV expressing 17 K RNA polymerase (pTF7.3)—kindly provided by Dr. B. Moss, N.I.H.) and one of the MHV proteins (m.o.i. = 2.5 for each). Cells were labeled with [35S]methionine (Amersham Corp., Arlington Heights, IL) from 12 to 14 hr p.i. (MHV-JHM) or from 5 to 7 hr p.i. (VV recombinants) in
methionine-free media. Lysates were prepared by treating cells with a solution containing 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 2 μg/ml aprotinin (Sigma Chemical Co., St. Louis, MO), 150 mM NaCl, and 10 mM Tris, pH 7.4. Viral proteins were precipitated with anti-MHV-JHM antibody (S protein), anti-M or anti-N monoclonal antibody (provided by Dr. M. Buchmeier, Scripps Clinic and Research Foundation) (Talbot et al., 1984), or anti-p28 polyclonal antibody (rabbit antibody directed against the p28 peptide containing amino acids 25–38). Antibody–antigen complexes were collected onto protein A–Sepharose (Pharmacia-LKB Biotechnology, Piscataway, NJ). Samples were analyzed by SDS–polyacrylamide gel electrophoresis (Maizel, 1971).

Proliferation assays

These assays were performed on immunized adult C57BL/6 mice and on persistently infected mice. First, using adult mice, we optimized conditions for splenocyte proliferation to MHV-JHM, based on published studies (Woodward et al., 1984). Intravenous, intraperitoneal, and subcutaneous routes of inoculation, with varying amounts of virus or viral antigen in the presence or absence of Freund’s adjuvant, were analyzed at different times after inoculation. Fetal calf serum (HyClone Laboratories, Inc., Logan, UT) and mouse serum were compared for their ability to support lymphocyte proliferation in vitro. The most reproducible measurements were performed using cells cultured from adult mice inoculated intraperitoneally with 1–2 × 10⁵ PFU of MHV-JHM without Freund’s adjuvant. Specific proliferation was optimal with fetal calf serum.

C57BL/6 mice were inoculated intraperitoneally with MHV-JHM in 0.5 ml phosphate-buffered saline (PBS). Eight days later, a single-cell suspension of spleen cells was prepared in RPMI 1640 medium containing 5 × 10⁻⁶ M 2-mercaptoethanol, 2 mM glutamine, 10% fetal calf serum (FCS), and antibiotics. Cells (2 × 10⁶) were cultured in 0.2 ml in the presence of 1:200 of antigen in 96-well round-bottom culture plates (Corning Inc., Corning, NY). Cells were also incubated in vitro with no antigen or with supernatant from concanavalin A-stimulated rat cells (positive control). After 4 days in culture at 37°, the cells were pulsed for 4 hr with 1 μCi/well [methyl-³H]thymidine (Amersham Corp.) and then harvested onto glass fiber filters (Skatron Instruments, Sterling, VA) with a cell harvester. Incorporated radioactivity was measured in a liquid scintillation counter (Beckman Instruments, Fullerton, CA). Each antigen was tested with six replicate wells.

To analyze the data, a mean proliferative response and standard error for each antigen were calculated for each group of mice (12 immunized adult mice and 6 persistently infected mice).

The proliferation index was calculated either as the ratio of stimulation by MHV-JHM-infected to uninfected cell lysate or as the ratio of stimulation by lysate from cells dually infected with vTF7.3 and VV expressing MHV protein to lysate from vTF7.3-infected cells. A proliferation index greater than 3 was considered significant (Wahren et al., 1981).

MHV-JHM antigen was prepared for use in the proliferation assays by infecting confluent DBT cells with MHV-JHM (m.o.i. = 1) and harvesting plates 12–14 hr later. For this purpose, cells were washed three times with PBS and scraped into PBS. Samples were briefly sonicated, clarified by centrifugation at 500 g for 10 min, and stored frozen in small aliquots at −70° (Woodward et al., 1984). Individual MHV antigens were prepared by dually infecting DBT cells with vTF7.3 and one of the VV recombinants expressing an MHV protein. After 7–14 hr, antigen was prepared as for MHV-JHM.

Immunofluorescence staining, analysis, and sorting

Preparation of cells for flow cytometry analysis was as previously described (Jung et al., 1988), using phycoerythrin-conjugated mAb MEL 14 and fluorococin conjugated anti-CD4 mAb GK1.5. Stained cells were analyzed and sorted on a FACS 440 (Becton Dickinson Immunocytometry Sys., Mountain View, CA). Fluorescence and light scatter signals were collected on 20,000 cells and analyzed using the FACS/DESK computer program.

Separation of lymphocytes by panning

Cultured splenocytes were incubated with saturating amounts of anti-CD8 mAb 53-6.7 and anti-B220 mAb RA3-6B2 for 20 min at 4° in RPMI 1640 with 10% FCS. The cells were washed and resuspended to a concentration of 1 × 10⁷ cells/ml, passed through a 30-gauge needle, and panned on goat anti-rat IgG-coated plastic petri dishes for 1 hr at 4°. Nonadherent, CD4⁺ T cells were incubated with MEL-14 and applied to new anti-rat pans for separation of gp90⁺ from gp90⁻ cells.

Assay for gamma interferon (IFN-γ)

A sandwich ELISA was used to quantify IFN-γ in tissue culture supernatants of stimulated and unstimulated sorted CD4⁺ T cells. Wells of an Immulon II plate were incubated with 100 μl of 10 μg/ml R4-6A2 (Sipatlny and Havell, 1984) (rat IgGl mAb to INF-γ in 0.1 M bicarbonate buffer, pH 9.6, for 1 hr at 37°. Wells were washed and the remaining protein binding sites were
blocked with 200 µl of RPM with 10% horse serum for 2 hr at room temperature. Next, 50 µl of tissue culture supernatants was added in triplicate wells for 1 hr at room temperature. The wells were washed and 100 µl of a 1:1000 dilution of polyclonal rabbit anti-INF-γ (kindly provided by D. Hoft, University of Iowa) in RPMI 1640 supplemented with 10% FCS was added for 45 min. After washing the wells, 100 µl of a 1:3000 dilution of HRP-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch Labs Inc., West Grove, PA) was added for 30 min. The wells were thoroughly washed and 100 µl of the HRP substrate ABTS (Kirkegaard and Perry Laboratories, Gaithersburg, MD) was added and the color change measured at 405 nm in a microplate ELISA reader (Bio-Tek Instruments Inc., Winooski, VT). A standard curve was generated using recombinant IFN-γ (Genentech, South San Francisco CA.)

**Assays for IL-2 and IL-4 production**

Bioassays of culture supernatants using the IL-2 indicator cell line CTLL-2 (ATCC) and IL-4 indicator cell line CT4S, kindly provided by Dr. William Paul, were performed as previously described (Hu-Li et al., 1989).

**RESULTS**

**Spleen cells from immunized and chronically infected mice proliferate in response to MHV-JHM antigen**

Adult C57BL/6 mice were immunized with MHV-JHM intraperitoneally, and 8 days later spleen cells were stimulated in vitro for 4 days with lysates of MHV-JHM-infected or uninfected cells at a 1:200 dilution. A strong proliferative response to MHV-JHM antigen was observed in all 12 mice analyzed (Fig. 1), whereas no significant proliferation was observed in vitro in the absence of in vivo priming with MHV-JHM (data not shown). The mean proliferation index (calculated as described under Materials and Methods) was 4.6.

Suckling C57BL/6 inoculated intranasally with virus and nursed by immunized dams often develop a late onset demyelinating encephalomyelitis characterized clinically by hindlimb paralysis (Perlman et al., 1987a). To determine if splenocytes from clinically ill, persistently infected mice also responded to MHV-JHM antigen, proliferation assays were performed on six mice with the onset of hindlimb paralysis 17–45 days p.i. A specific proliferative response similar to that observed in the immunized population was detected, with a mean proliferation index of 6.3 (Fig. 2).

**Surface and transmembrane glycoproteins are stimulants for proliferation**

To determine the antigen specificity of T cell proliferation in vitro, VV recombinants expressing the MHV structural proteins, S, M, and N and the nonstructural protein, p28, were constructed as described under Materials and Methods. P28, a basic protein encoded by the putative MHV polymerase gene (Denison and Perlman, 1986; Soe et al., 1987) was included in these

**Fig. 1. Cell proliferative response in immunized mice.** Twelve mice were infected i.p. with 1–2 x 10⁶ PFU MHV-JHM. Splenocytes were analyzed 8 days p.i. as described under Materials and Methods. The mean number of counts incorporated and the standard error in response to each DBT lysate are shown. JHM, MHV-JHM-infected cells; uninf, uninfected cells; S, M, N, p28, cells dually infected with vTF7.3 and VV encoding the respective MHV protein; T7, cells infected with vTF7.3; none, no added antigen.

**Fig. 2. Cell proliferation response in persistently infected mice.** Splenocytes from six mice with hindlimb paralysis were analyzed as described under Materials and Methods. The mean number of counts incorporated and the standard error in response to each lysate are shown. The six mice developed hindlimb paralysis at 17, 19, 26, 29, 45, and 45 days p.i. Lysates are as those in Fig. 1.
MHV protein synthesis was assayed by infecting DBT cells with MHV-JHM or with vTF7.3 and VV recombinants expressing MHV proteins. Controls included uninfected DBT cells and cells infected with vTF7.3 alone. Lysates were prepared from [35S]methionine-labeled cells as described under Materials and Methods and reacted with (A) rabbit anti-MHV-JHM antibody; (B) anti-N monoclonal antibody; (C) anti-M monoclonal antibody; (D) rabbit anti-p28 antibody. Proteins were analyzed by SDS-PAGE. J, MHV-JHM-infected lysate; T7, vTF7.3-infected lysate; S, N, M, p28, lysates infected with vTF7.3 and recombinants encoding the S, N, M, and p28 proteins. *, MHV-specific proteins encoded by VV recombinants; ●, in (D) marks p28 present in J and absent in U.

studies since analysis of its structure indicated the presence of several possible T cell epitopes (Margalit et al., 1987).

To prove that each construct produced the MHV protein of interest, DBT cells were dually infected with vaccinia expressing T7 polymerase (vTF7.3) and one of the VV recombinants. Protein products were analyzed by radioimmunoprecipitation and SDS–polyacrylamide gel electrophoresis (Fig. 3). The S gene (Fig. 3A) coded for a protein which was 141 aa smaller than wild-type MHV-JHM S protein as described previously (Schmidt et al., 1987; Parker et al., 1989). The VV recombinant containing the N sequence expressed an appropriately sized nucleocapsid protein when similarly analyzed by immunoprecipitation and SDS–PAGE (Fig. 3B).

The VV recombinant containing the M sequence (Fig. 3C) expressed two proteins. The most abundant protein migrated more slowly than the M protein detected in MHV-infected cells, whereas the less abundant protein migrated identically to the M protein present in these cells. The two proteins expressed by the VV recombinants most likely differ in the degree of glycosylation and since the slightly larger protein was not observed when other cell lines were infected with the VV recombinant, its structure was not further investigated.

MHV-JHM p28 is normally cleaved from a larger precursor (Denison and Perlman, 1986), although the precise site of cleavage has not been identified. P28 was detected by immunoprecipitation in MHV-JHM-infected but not in uninfected cells (Fig. 3D). For the construction of the VV recombinant containing the p28 sequence, a termination codon was introduced at a possible cleavage site (Soo et al., 1987) as described under Materials and Methods. When cells were infected with the VV recombinant containing the p28 sequence, a protein migrating at approximately 32 kDa was detected with anti-p28 antibody (Fig. 3D). The most likely explanation for the discrepancy in molecular weight between this protein and the 28-kDa product present in MHV-JHM-infected cells was that the termination codon introduced into the downstream primer was placed 3' to the true cleavage site, resulting in a larger protein.

For use in cell proliferation assays, unlabeled cell lysates were prepared from DBT cells co-infected with vTF7.3 and the MHV VV recombinants. To determine the amount of each MHV protein synthesized relative to that observed in cells infected with MHV-JHM, equal volumes of the N, S, p28, and MHV-JHM-infected DBT lysates were compared by protein blot analysis. These results showed that equal or greater amounts of each MHV protein were present in the VV recombinant lysates when compared to MHV-infected cells (data not shown). Splenocytes from immunized and from persistently infected mice with hindlimb paralysis were incubated with VV-infected DBT lysates which expressed only a single MHV protein. Lysates from cells infected only with vTF7.3 were used as a negative control.

Cells from immunized mice showed significant proliferation in response to the surface and transmembrane glycoproteins with no response to the N or p28 proteins. The mean proliferation index was 3.5 for the S protein and 3.3 for the M protein. The sum of the proliferative responses to the M and S proteins was very similar to the response measured with the MHV-JHM lysate, suggesting that these two proteins accounted for most of the proliferative activity.

A different pattern of stimulation was measured in mice persistently infected with MHV-JHM. Splenocytes from these mice proliferated significantly only to lysate expressing the S protein, with a proliferation index of 6.7. The amount of S protein-specific proliferation was nearly equal to that observed with the MHV-JHM lysate, suggesting that the S protein was the major antigen recognized by these lymphocytes.

CD4+gp90+ cells proliferate in response to MHV-JHM

In the next set of experiments, we determined which type of lymphocyte proliferated in response to viral an-
TABLE 1

PROLIFERATIVE RESPONSE OF CD4+ AND CD4- LYMPHOCYTES FROM IMMUNIZED ADULT MICE

| Mouse no. | CD4+ a cpm | CD4- a cpm | CD4+ b / CD4- b | %CD4+ c / %CD4- c | %CD4+ d proliferation |
|-----------|------------|------------|-----------------|-------------------|------------------|
| 1         | 8882       | 1733       | 5.1             | 31.8              | 71               |
| 2         | 4276       | 902        | 4.7             | 32.6              | 70               |
| 3         | 4707       | 1984       | 2.4             | 40.8              | 62               |
| 4         | 50243      | 17483      | 2.9             | 39.0              | 66               |
| 5         | 69475      | 33733      | 2.1             | 41.7              | 60               |
| 6         | 28280      | 13190      | 2.1             | 53.6              | 71               |

a CD4+ and CD4- cells were prepared from MHV-JHM-stimulated cultures. 30,000 cells/well were labeled with [3H]thymidine. cpm represents means of triplicate samples.

b Relative proliferation of purified CD4+/CD4- cells.

c Proportion of CD4+ cells in the culture as determined by FACS analysis.

d Percentage of total proliferation in the culture which is from CD4+ cells: [(CD4+ cpm) x %CD4+]/[(CD4+ cpm) x %CD4+ + (CD4- cpm) x (100 - %CD4+)].

To characterize further the phenotype of cells proliferating in response to antigen, CD4+ cells were prepared from cultures which had been incubated for 4 days with MHV-JHM antigen. These cells were fractionated into gp90+ and gp90- populations by panning, and [3H]thymidine uptake was measured. As shown in Table 2, the CD4+gp90- population was 10–15 times more active on a per cell basis than the CD4+gp90+ population.

IFN-γ production in response to MHV-JHM

Since activated lymphocytes secrete specific cytokines to enhance and modulate the antiviral response, we assayed cell supernatants after 3–5 days in vitro for IL-2, IL-4, and IFN-γ. We could not detect any antigen-specific release of IL-2 and IL-4 since both MHV-JHM- and control stimulated cultures secreted equivalent, relatively low amounts (data not shown). In contrast, IFN-γ was produced in greater quantities by MHV-JHM-stimulated cells (6.54 units–S.E. 2.45) than by control cultures (0.97 units–S.E. 0.27) as shown in Fig. 5.

To determine the phenotype of the cells which actually produced IFN-γ, CD4+ cells from three mice were prepared after 4 days in vitro and separated into gp90+ and gp90- fractions by panning. Separated cells were then incubated in vitro for 24 hr and IFN-γ activity was measured in each supernatant. Anti-CD3 was added to replicate wells, a technique frequently used to enhance secretion in lymphokine assays.

Little difference was noted in interferon-γ production by the gp90- and gp90+ cultures in the absence of anti-CD3 or specific antigen (Fig. 6), in agreement with previous observations in other systems (Fortier et al., 1989). However, after stimulation with anti-CD3 antibody, large amounts of IFN-γ were produced by the gp90- cells, whereas secretion by gp90+ lymphocytes was barely detectable (Fig. 6). These results suggest that the CD4+gp90- T cells, shown previously to be the ones most actively proliferating in response to antigen, were also the source of IFN-γ produced in the MHV-stimulated cell cultures.

DISCUSSION

Adult C57BL/6 mice, like many other strains, are very susceptible to infection with MHV-JHM (Stohlman and Frelinger, 1978). In addition, suckling C57BL/6 mice, even if protected from acute encephalitis by ma-
ternal antibody, develop a clinically apparent demyelinating encephalomyelitis 3–8 weeks after intranasal inoculation (Perlman et al., 1987a). Suckling BALB/c mice, another susceptible strain, are also protected from acute encephalitis by nursing by immunized dams, but, unlike C57BL/6 mice, do not develop a late onset, demyelinating encephalomyelitis (Perlman et al., 1987b). Thus, the immune response to MHV-JHM may be particularly suboptimal in C57BL/6 mice infected with MHV-JHM.

Cytotoxic CD8+ cells are believed to be critical for resolution of viral infections, including the CNS infection caused by MHV-JHM (Sussman et al., 1989; Williamson and Stohlman, 1990; Yamaguchi et al., 1991). In ongoing studies, we have been unable to demonstrate cytotoxic T cell (CTL) activity against MHV-JHM in spleen cell preparations from immunized mice (S. Perlman, unpublished observations). Measurement of CTL activity from C57BL/6 mice is hindered by the lack of a convenient syngeneic target which can be infected by MHV. However, VV does infect syngeneic target cells and using our VV recombinants, we were unable to identify a significant CTL response to the N, M, S, or p28 proteins. While there are several explanations for this data, one possibility is that CTL activity against MHV-JHM is insubstantial in C57BL/6 mice and that this is a component of the ineffective immune response to the virus.

In contrast to the minimal CTL response observed in C57BL/6 mice, we easily detected a strong proliferative response to MHV antigen after in vitro culture of lymphocytes from immunized adult or persistently infected mice. The response was quantitatively the

![Fig. 4. Two-color flow cytometric analysis of CD4 and gp90 on cells proliferating in response to MHV-JHM-infected and uninfected lysates. After 4 days in vitro, cells were analyzed as described under Materials and Methods using the fluorescence-activated cell sorter. The arrow indicates the population of gp90+ cells present predominantly in the MHV-JHM-stimulated cultures.](image-url)

![Fig. 5. IFN-γ production. IFN-γ was assayed from supernatants of unfractionated spleen cells incubated in vitro for 3 days (mouse No. 1 and 2) or 4 days (mouse No. 3, 4, and 5) with MHV-JHM-infected or uninfected DBT lysates as described under Materials and Methods. Measurements were made in triplicate and the standard error is indicated above each bar.](image-url)
the N and S proteins were shown to suppress viral infected animals. Other studies have shown that monomeric transmembrane protein solely in the persistently in-

FIG. 6. IFN-γ production in CD4+gp90+ and CD4+gp90− cells. After 4 days in vitro, cells were panned for CD4+ cells which, in turn, were fractionated into gp90+ and gp90− populations. 3 × 10⁶ gp90+ and gp90− cells were incubated in vitro for an additional 24 hr in the presence or absence of anti-CD3 antibody. IFN-γ activity was measured in the supernatants as described under Materials and Methods. Data from triplicate cultures of three separate mice are shown, with the standard error indicated above each bar.

same in the two groups of mice and in both cases, the S surface glycoprotein was an effective stimulator for proliferation. An important difference between the two groups was the absence of cells responsive to the M transmembrane protein solely in the persistently infected animals. Other studies have shown that monoclonal antibodies to the M protein protect mice from the acute encephalitis (Fleming et al., 1989) and our results raise the possibility that cell-mediated recognition of this protein may be an important part of an effec-
tive immune response to MHV-JHM.

Recent studies have documented the importance of CD4+ cells in suppressing neurological infections caused by MHV-JHM in both mice and rats (Williamson and Stohlman, 1990; Yamaguchi et al., 1991; Korner et al., 1991). In one of these studies, CD4+ cells specific for the N and S proteins were shown to suppress viral replication in rats. The N protein elicited a stronger proliferative response than did the S protein in these animals (Korner et al., 1991). The lack of recognition of the N protein after immunization or persistent infection may also contribute to the relatively ineffective immune response to MHV-JHM in C57BL/6 mice.

The cells which proliferate in response to MHV-JHM antigen secrete IFN-γ. Since IFN-γ is secreted by the TH1 subset of CD4+ cells, it is likely that MHV-JHM antigen preferentially stimulates this subset of helper T cells in C57BL/6 mice. This stimulation of TH1-like cells may be strain-dependent as well as antigen-de-


tential, since C57BL/6 mice show a preferential TH1-like response under conditions in which other strains show a TH2-like response (Street and Mose-
nan, 1991). TH1 cells secrete IL-2 in addition to IFN-

ACKNOWLEDGMENTS

We thank Dr. S. Siddell for providing clones containing the MHV-JHM sequences, Dr. M. Buchmeier for anti-M and -N monoclonal antibodies, Dr. S. Weiss for MHV-A59 clone 344, and Dr. B. Moss for pTM3 and VV recombinant pTF7.3. We thank Dr. C. M. Stoltzfus for helpful discussions and for critical review of the manuscript. This research was supported by grants from the N.I.H. (NS24401 and AI02733) and from the National Multiple Sclerosis Society (RG2117-A-1). S.P. was supported by a Research Career Development Award (NS01369) from the N.I.H.

REFERENCES

BRADLEY, L., DUNCAN, D., TONKONOGY, S., and SWAIN, S. (1991). Characterization of antigen-specific CD4+ effector T cells in vivo: Immunization results in a transient population of MEL14−, CD45RB− helper cells that secrete interleukin 2 (IL-2), IL-3, IL-4 and interferon gamma. J. Exp. Med. 174, 547–559.

RUTHEMUR, M. I., IWAZUKI, H. A., TIA ROTH, P. I., and KNOBLER, R. L. (1984). Murine hepatitis virus-4 (strain JHM)-induced neurological disease is modulated in vivo by monoclonal antibody. Virology 132, 261–270.

CARMAN, P. S., ERNST, P. E., ROSENTHAL, K. L., CLARK, D. A., BEFUS, A. D., and BIENSENSTOCK, J. (1986). Intraepithelial leukocytes contain a unique subpopulation of NK-like cytotoxic cells active in the defense of epithelium to enteric murine coronavirus. J. Immunol. 136, 1548–1553.

CHEEVER, F. S., DANIELS, J. B., PAPPENHEIMER, A. M., and BAILEY, Ô. T. (1980). A murine virus (JHM) causing distempered encephalomyelitis with extensive destruction of myelin. J. Exp. Med. 150, 181–194.

DAILEY, M. O., GALLATIN, W. M., and WEISSMAN, I. L. (1985). The in vivo behavior of T cell clones: Altered migration due to loss of the
lymphocyte surface homing receptor. J. Mol. Cell. Immunol. 2, 27–35.

Denison, M. R., and Perlman, S. (1986). Translation and processing of mouse hepatitis virus vion RNA in a cell-free system. J. Virol. 60, 12–18.

Elroy-Stein, O., and Moss, B. (1990). Cytoplasmic expression system based on constitutive synthesis of bacteriophage T7 RNA polymerase in mammalian cells. Proc. Natl. Acad. Sci. USA 87, 6743–6747.

Falkner, F. G., and Moss, B. (1988). Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J. Virol. 62, 1849–1854.

Fleming, J. O., Shubin, R., Sussman, M., Casteel, N., and Stohlman, S. A. (1989). Monoclonal antibodies to the matrix (E1) glycoprotein of mouse hepatitis virus protect mice from encephalitis. Virology 186, 182–187.

Forter, A. H., Naoy, C. A., and Sitkovsky, M. V. (1989). Similar molecular requirements for antigen receptor-triggered secretion of interferon and granule enzymes by cytolytic T lymphocytes. Cell. Immunol. 124, 64–76.

Gallatin, W. M., Weissman, I. L., and Butcher, E. C. (1983). A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature 304, 30–34.

Hirano, N., Fujimura, K., Iino, S., and Matumoto, M. (1971). Repli-
cation and plaque formation of mouse hepatitis virus (MHV-2) in mouse cell line DBT cultures. Arch. Ges. Virusforsch. 44, 298–302.

Hu-Li, J., Ohara, J., Watson, C., Tsang, W., and Paul, W. E. (1989). Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S). J. Immunol. 142, 800–807.

Jacobson, G., and Perlman, S. (1990). Localization of virus and antibody response in mice infected persistently with MHV-JHM in mouse cell line DBT cultures. Arch. Ges. Virusforsch. 44, 298–302.

Jung, T. M., Gallatin, W. T., Weissman, I. L., and Dailey, M. O. (1988). Down-regulation of homing receptors after T cell activation. J. Immunol. 141, 4110–4117.

Korner, H., Schliephake, A., Winter, J., Zimprich, F., Lassman, H., Sedwick, J., Siddell, S., and Wenge, H. (1991). Nucleocapsid or spike protein-specific CD4+ T lymphocytes protect against coronavirus-induced encephalomyelitis in the absence of CD8+ T cells. J. Immunol. 147, 2317–2323.

Lampert, P. W., Sims, J. K., and Knazeff, A. J. (1973). Mechanism of demyelination in JHM virus encephalomyelitis. Acta Neuropathol. 24, 76–85.

Leonciti, J., Canelli, G., Manzoni, M., and Del Giudice, M. (1988). Variables affecting the maintenance of retroviral-induced lymphocytes. Methods Virol. 1, 170–246.

Margalit, H., Spouge, J. L., Cornette, J. L., Cease, K. B., Delisi, C., and Benacerraf, B. (1987). Prediction of immunodominant helper T cell antigenic sites from the primary sequence. J. Immunol. 138, 2213–2222.

Nakazawa, K., Wueke, H., Mierremann, R., and Jebbar, V. (1986). The role of the E2 glycoprotein in the pathogenesis of murine encephalomyelitis induced by a recombinant vaccinia virus vector. Virology 161, 122–132.

Parker, S. E., Gallagher, T. M., and Buchmeier, M. J. (1989). Sequence analysis reveals extensive polymorphism and evidence of deletions within the E2 glycoprotein gene of several strains of murine hepatitis virus. Virology 173, 664–673.

Perlman, S., Schepelar, R., Bolger, E., and Ries, D. (1987a). Late onset, symptomatic, demyelinating encephalomyelitis in mice infected with MHV-JHM in the presence of maternal antibody. Microbiol. Pathol. 2, 153–159.

Perlman, S., Schepelar, R., and Ries, D. (1987b). Maternal antibody-mediated MHV-JHM infection in C57Bl/6 and Balb/c mice. Adv. Exp. Med. Biol. 218, 297–305.

Pfeifer, M., Skinner, M. A., and Siddell, S. G. (1986). Coronavirus virus MHV-JHM: Nucleotide sequence of the mRNA that encodes the membrane protein. Nucleic Acids Res. 14, 6338.

Picket, K., Muller, M. A., and Ten Meulend, V. (1985). Influence of maternal immunity on the outcome of murine coronavirus JHM infection in suckling mice. Med. Microbial. Immunol. 174, 16–24.

Sambrook, J. F., Fritsch, E. E., and Maniatis, T. (1989). “Molecular Cloning: A Laboratory Manual,” chap. 14. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

Stern, N., and Mosmann, T. (1991). Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J. 5, 171–177.

Stohlman, S. A., Matsushita, K. G., Casteel, N., and Weiner, L. P. (1986). In vivo effects of coronavirus-specific T cell clones: DTH inducer cells prevent a lethal infection but do not inhibit virus repli-
cation. J. Immunol. 136, 3052–3056.

Stohlman, S. A., and Weiner, L. P. (1981). Chronic central nervous system demyelination in mice after JHM virus infection. Neurology 31, 309–314.

Stohlman, S. A., and Frelinger, J. A. (1978). Resistance to fatal central nervous system disease by mouse hepatitis virus, strain JHM. Immunogenetics 6, 277–281.

Sussman, M. A., Matsushita, K. G., Casteel, N., and Stohlman, S. A. (1989). T-cell-mediated clearance of mouse hepatitis virus strain JHM from the central nervous system. J. Virol. 63, 3051–3056.

Talbott, P. T., Salmin, A. A., and Buchmeier, M. J. (1984). Topographical mapping of epitopes on the glycoproteins of murine hepatitis virus-4 (strain JHM): Correlation with biological activities. Virology 168, 250–260.

Wahle, R., Niranjan, P., and Niranjan, S. (1981). Conditions for demyelination of lymphocytes. Scand. J. Immunol. 13, 581–586.
WANG, F., STOHLMAN, S., and FLEMING, J. O. (1990). Demyelination induced by murine hepatitis virus JHM strain (MHV-4) is immunologically mediated. J. Neuroimmunol. 30, 31–41.

WATANABE, R., WEGE, H., and TER MEULEN, V. (1983). Adoptive transfer of EAE-like lesions from rats with coronavirus-induced demyelinating encephalomyelitis. Nature 305, 150–153.

WATANABE, R., WEGE, H., and TER MEULEN, V. (1987). Comparative analysis of coronavirus JHM-induced demyelinating encephalomyelitis in Lewis and Brown Norway rats. Lab. Invest. 57, 375–384.

WEINER, L. P. (1973). Pathogenesis of demyelination induced by a mouse hepatitis virus. Arch. Neural. 28, 298–303.

WENSH, R. M., HARPE, H. V., PARKER, D. C., and HOLMES, K. V. (1986). Natural cytotoxicity against mouse hepatitis virus infected cells. II. A cytotoxic effector cell with a B lymphocyte phenotype. J. Immunol. 136, 1454–1460.

WILLIAMSON, J. S., and STOHLMAN, S. A. (1990). Effective clearance of mouse hepatitis virus from the central nervous system requires both CD4+ and CD8+ T cells. J. Virol. 64, 4589–4592.

WOODWARD, J., MATSUSHIMA, G., FRELINGER, J. A., and STOHLMAN, S. A. (1984). Production and characterization of T cell clones specific for mouse hepatitis virus, strain JHM: In vivo and in vitro analysis. J. Immunol. 133, 1016–1021.

YAMAGUCHI, K., GOTO, N., KIYOSWA, S., HAYAMI, M., and TOYODA, Y. (1991). Protection of mice from a lethal coronavirus infection in the central nervous system by adoptive transfer of virus-specific T cell clones. J. Neuroimmunol. 32, 1–9.

ZIMMER, M. J., and NALES, S. (1989). In vivo and in vitro models of demyelinating diseases. XXIV. The infectious process in cyclosporin A treated Wistar Lewis rats inoculated with JHM virus. Microbial. Pathog. 6, 7–18.